Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study (DUALING)
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study.
Sponsor: Admiraal de Ruyter Hospital
Listed as NCT04707326, this observational or N/A phase trial focuses on Hiv and remains ongoing. Sponsored by Admiraal de Ruyter Hospital, it has been updated 5 times since 2019, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Jan 2025 — Present [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2022 — Jul 2024 [monthly]
Recruiting
-
Feb 2021 — Feb 2022 [monthly]
Recruiting
First recorded
Nov 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Admiraal de Ruyter Hospital
- Catharina Ziekenhuis Eindhoven
- Elisabeth-TweeSteden Ziekenhuis
- Erasmus Medical Center
- Haaglanden Medical Centre
- Maasstad Hospital
- Medisch Spectrum Twente
- Rijnstate Hospital
- Spaarne Gasthuis
For direct contact, visit the study record on ClinicalTrials.gov .